Zobrazeno 1 - 10
of 410
pro vyhledávání: '"Ulrike, Leiter"'
Autor:
Ralf Gutzmer, Ulrike Leiter, Peter Mohr, Katharina C. Kähler, Paolo Antonio Ascierto, Massimiliano Scalvenzi, Ketty Peris, Gemma María Pérez-Pastor, Ricardo Fernández-de-Misa, Rafael Botella-Estrada, Robert E. Hunger, Serena Martelli, Nur Güneli, Ramon Arntz, Axel Hauschild
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background Following the pivotal phase II trial BOLT, the Hedgehog (Hh) inhibitor sonidegib was approved in the EU to treat locally advanced basal cell carcinoma (laBCC) in patients not amenable to surgery or radiotherapy. We report safety d
Externí odkaz:
https://doaj.org/article/f6af041d3b7c44cf9ec6506be11d5de8
Autor:
Lisa Wiens, Gerd Grözinger, Helmut Dittmann, Karolin Thiel, Ulrike Leiter, Teresa Amaral, Lena Nanz, Lukas Flatz, Andrea Forschner
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Uveal melanoma is the most common malignant tumor of the eye in adults. About half of the patients develop distant metastases, most commonly liver metastases (>90%). These are associated with poorer overall survival compared to patients w
Externí odkaz:
https://doaj.org/article/b78e3bcdd36e47719be5e1d9b1f76552
Autor:
Elias A. T. Koch, Anne Petzold, Edgar Dippel, Michael Erdmann, Anja Gesierich, Ralf Gutzmer, Jessica C. Hassel, Sebastian Haferkamp, Katharina C. Kähler, Nicole Kreuzberg, Ulrike Leiter, Carmen Loquai, Friedegund Meier, Markus Meissner, Peter Mohr, Claudia Pföhler, Farnaz Rahimi, Beatrice Schell, Patrick Terheyden, Kai-Martin Thoms, Selma Ugurel, Jens Ulrich, Jochen Utikal, Michael Weichenthal, Fabian Ziller, Carola Berking, Markus V. Heppt
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionDespite recent advancements in the treatment of metastatic uveal melanoma (UM), the availability of further treatment options remains limited and the prognosis continues to be poor in many cases. In addition to tebentafusp, immune checkpo
Externí odkaz:
https://doaj.org/article/e37aacd9f05d43b681af7a4bbdfeb024
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionCombined immune checkpoint inhibition (ICI) with ipilimumab and nivolumab is a widely used treatment regimen for metastatic melanoma with non-resectable metastases. Nevertheless, the standard dose of ipilimumab 3 mg/kg bw and nivolumab 1
Externí odkaz:
https://doaj.org/article/ceb67aa294dc4f9797190022c91f9626
Autor:
Dirk Schadendorf, Carola Berking, Lisa Zimmer, Ralf Gutzmer, Alexander Kreuter, Andrea Forschner, Elisabeth Livingstone, Bastian Schilling, Selma Ugurel, Peter Mohr, Jessica Hassel, Patrick Terheyden, Henner Stege, Katharina Kaehler, Sebastian Haferkamp, Friedegund Meier, Claudia Pfoehler, Dirk Debus, Rudolf Herbst, Carmen Loquai, Frank Meiss, Martin Kaatz, Jens Ulrich, Edgar Dippel, Michael Weichenthal, Ulrike Leiter, Markus V Heppt, Michael Sachse, Fabian Ziller, Stephan Grabbe, Georg Lodde, Maximilian Haist, Friederike Rogall, Yuqi Tan, Kai Christian Klespe, Michael Tronnier, Imke von Wasielewski, Felix Kieker, Christopher Gebhardt, Jan Simon
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/85987b665cf74916884422bf2059f401
Autor:
Alexandra Liebmann, Jakob Admard, Sorin Armeanu-Ebinger, Hannah Wild, Michael Abele, Axel Gschwind, Olga Seibel-Kelemen, Christian Seitz, Irina Bonzheim, Olaf Riess, German Demidov, Marc Sturm, Malou Schadeck, Michaela Pogoda, Ewa Bien, Malgorzata Krawczyk, Eva Jüttner, Thomas Mentzel, Maja Cesen, Elke Pfaff, Michal Kunc, Stephan Forchhammer, Andrea Forschner, Ulrike Leiter-Stöppke, Thomas K. Eigentler, Dominik T. Schneider, Christopher Schroeder, Stephan Ossowski, Ines B. Brecht
Publikováno v:
EBioMedicine, Vol 96, Iss , Pp 104797- (2023)
Summary: Background: Genomic characterisation has led to an improved understanding of adult melanoma. However, the aetiology of melanoma in children is still unclear and identifying the correct diagnosis and therapeutic strategies remains challenging
Externí odkaz:
https://doaj.org/article/127dec53e6d3434d85e40f46cbf6798e
Autor:
Dirk Schadendorf, Carola Berking, Jessica C Hassel, Lisa Zimmer, Ralf Gutzmer, Alexander Kreuter, Andrea Forschner, Bastian Schilling, Selma Ugurel, Katharina C Kähler, Peter Mohr, Patrick Terheyden, Felix Kiecker, Henner Stege, Sebastian Haferkamp, Friedegund Meier, Claudia Pfoehler, Dirk Debus, Rudolf Herbst, Carmen Loquai, Frank Meiss, Martin Kaatz, Jens Ulrich, Edgar Dippel, Michael Weichenthal, Axel Hauschild, Ulrike Leiter, Markus V Heppt, Christoffer Gebhardt, Michael Sachse, Fabian Ziller, Stephan Grabbe, Georg Lodde, Maximilian Haist, Friederike Rogall, Yuqi Tan, Imke von Wasielewski, Kai Christian Klespe, Michael Tronnier, Jan Christoph Simon
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 9 (2023)
Background Adjuvant therapy with immune-checkpoint inhibitors (CPI) or BRAF/MEK-directed targeted therapy (TT) improves recurrence-free survival (RFS) for patients with advanced, BRAFV600-mutant (BRAFmut) resected melanoma. However, 40% of these pati
Externí odkaz:
https://doaj.org/article/b02d789393944e89a582fe64cc6e6ada
Autor:
Lucie Heinzerling, Lisa Zimmer, Ralf Gutzmer, Andrea Forschner, Elisabeth Livingstone, Bastian Schilling, Selma Ugurel, Peter Mohr, Thilo Gambichler, Patrick Terheyden, Sebastian Haferkamp, Dirk Debus, Rudolf Herbst, Carmen Loquai, Frank Meiss, Carsten Weishaupt, Martin Kaatz, Jens Ulrich, Edgar Dippel, Michael Weichenthal, Maike Trommer, Jürgen Christian Becker, Ulrike Leiter, Cindy Franklin, Christoffer Gebhardt, Katharina Kahler, Leonie Bluhm, Imke Grimmelmann, Marlene Garzarolli, Dorothee Nashan, Michael Sachse, Julia Welzel, Gerhard Weyandt, Susanne Horn, Fabian Ziller, Harald Löffler, Stephan Grabbe, Gaston Schley, Georg Lodde, Jan-Malte Placke, Anca Sindrilaru
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 4 (2023)
Background Despite the availability of effective systemic therapies, a significant number of advanced melanoma patients develops brain metastases. This study investigated differences in incidence and time to diagnosis of brain metastasis and survival
Externí odkaz:
https://doaj.org/article/78c357556a7d4fdbba1d2ae0e5644ffc
Autor:
Ulrike Leiter, Markus V. Heppt, Theresa Steeb, Mareike Alter, Teresa Amaral, Andrea Bauer, Falk G. Bechara, Jürgen C. Becker, Eckhard W. Breitbart, Helmut Breuninger, Thomas Diepgen, Thomas Dirschka, Thomas Eigentler, A.K. Stephan El Gammal, Moritz Felcht, Michael J. Flaig, Markus Follmann, Klaus Fritz, Stephan Grabbe, Rüdiger Greinert, Ralf Gutzmer, Axel Hauschild, Uwe Hillen, Stephan Ihrler, Swen Malte John, Lukas Kofler, Oliver Koelbl, Albrecht Krause-Bergmann, Klaus Kraywinkel, Steffen Krohn, Thomas Langer, Carmen Loquai, Christoph R. Löser, Peter Mohr, Dorothée Nashan, Monika Nothacker, Christina Pfannenberg, Carmen Salavastru, Lutz Schmitz, Eggert Stockfleth, Rolf-Markus Szeimies, Claas Ulrich, Susanne Voelter-Mahlknecht, Dirk Vordermark, Michael Weichenthal, Julia Welzel, Kai Wermker, Susanne Wiegand, Claus Garbe, Carola Berking
Publikováno v:
EJC Skin Cancer, Vol 1, Iss , Pp 100004- (2023)
Actinic keratosis (AK) are common lesions in light-skinned individuals that can potentially progress to cutaneous squamous cell carcinoma (cSCC). Both conditions may be associated with significant morbidity and constitute a major disease burden, espe
Externí odkaz:
https://doaj.org/article/85150b273461404ea9bcf7212bcf4400
Autor:
Dirk Schadendorf, Lisa Zimmer, Bastian Schilling, Selma Ugurel, Valerie Glutsch, Anja Gesierich, Matthias Goebeler, Jürgen C Becker, Sebastian Haferkamp, Christian Posch, Michael Weichenthal, Ulrike Leiter, Christoffer Gebhardt, Patrick Schummer, Hermann Kneitz, Detlef Klein
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 11 (2022)
Merkel cell carcinoma is a rare, highly aggressive skin cancer with neuroendocrine differentiation. Immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease with response rates to programmed cell death protein
Externí odkaz:
https://doaj.org/article/1cc2750e45564ddcada930fb89b042c9